



Nano-Based Technology for Glioblastoma

Guest Editors:

Dr. Maria João Ramalho

1. LEPABE—Laboratory for Process Engineering, Environment, Biotechnology and Energy, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal

2. ALiCE—Associate Laboratory in Chemical Engineering, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal

Dr. Joana Peixoto

1. i3S - i3S—Institute for Research and Innovation in Health, University of Porto, 4200-135 Porto, Portugal

2. LEPABE—Laboratory for Process Engineering, Environment, Biotechnology and Energy, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal

Message from the Guest Editors

Dear Colleagues,

Nano-based technology offers promising avenues for treating glioblastoma, the most common and deadliest form of primary brain cancer in adults. Innovative approaches utilizing nanoparticles to deliver therapeutic agents directly to tumor cells have been successfully designed to enhance drug efficacy while minimizing off-target effects. Nanoparticles can not only penetrate the blood–brain barrier, allowing for targeted drug delivery to tumor cells, but can also be engineered to release drugs in response to specific stimuli within the tumor microenvironment.

This Special Issue aims to include original research articles and reviews within, but not limited to, the following research areas: design and development of nanoparticles that specifically target glioblastoma cells; strategies to enhance the ability of nanoparticles to penetrate the blood–brain barrier; engineering stimuli-responsive nanoparticles or immunomodulatory nanoparticles; nano-delivery platforms for combination therapies; imaging, diagnosis, and theranostics with nano-based systems, among others.

We look forward to receiving your contributions.

Deadline for manuscript submissions:

31 October 2024



mdpi.com/si/202645



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceutics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma